UPCC 01617: A Study to Evaluate the Safety and Efficacy of the CD40 Agonistic Antibody APX005M Administered in Combination with Nivolumab in Subjects with Non-small Cell Lung Cancer and Subjects with Metastatic Melanoma
Enrolling By Invitation
99 years or below
All
Phase
2
10 participants needed
1 Location
Brief description of study
Request for collaborative review: WIRB serving as IRB of record.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Cancer', 'Non Small Cell Lung Cancer Metastatic', 'Metastatic Melanoma', 'Neoplasm of Lung', 'Melanoma
-
Age: 99 years or below
-
Gender: All
Updated on
19 Feb 2024.
Study ID: 827441
If you need help finding a study or have any questions, please contact us at psom-ocr@pobox.upenn.edu
